Holen Sie sich die Stockscreener-App
8.17
2.27%
-0.19
Handel nachbörslich:
8.17
Schlusskurs vom Vortag:
$8.36
Offen:
$8.35
24-Stunden-Volumen:
55,639
Relative Volume:
0.93
Marktkapitalisierung:
$299.93M
Einnahmen:
$4.90M
Nettoeinkommen (Verlust:
$-173.80M
KGV:
-1.7067
EPS:
-4.787
Netto-Cashflow:
$-26.31M
1W Leistung:
-3.43%
1M Leistung:
-36.76%
6M Leistung:
+13.16%
1J Leistung:
+332.28%
1-Tages-Spanne:
$8.00
$8.92
1-Wochen-Bereich:
$7.4701
$8.99
52-Wochen-Spanne:
$1.74
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Firmenname
Armata Pharmaceuticals Inc
Sektor
Branche
Telefon
310-655-2928
Adresse
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
8.17 | 306.90M | 4.90M | -173.80M | -26.31M | -4.787 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-06-19 | Eingeleitet | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline ProgressFinal Results - Newser
ARMP Stock Chart | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Why Is Armata Pharmaceuticals, Inc. (ARMP) Stock Down Today? - Meyka
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Armata Pharmaceuticals 1Q Loss/Shr $3.16 >ARMP - Moomoo
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ARMP: Armata Reports Increased Revenue and Focuses on Phase 3 Tr - GuruFocus
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update - TradingView
Armata Secures New Loan Amid Wider Quarterly Loss - TipRanks
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata Pharmaceuticals, Inc. 1Q 2026: Revenue $789K, EPS ($3.16) — 10-Q Summary - TradingView
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
ARMP Technical Analysis | Trend, Signals & Chart Patterns | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
FDA grants fast track status to Armata’s bacterial infection drug By Investing.com - Investing.com India
Armata Gains FDA Fast Track for AP-SA02 Therapy - TipRanks
FDA grants fast track status to Armata’s bacterial infection drug - Investing.com India
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PR Newswire
MSN Money - MSN
The industry tailwinds powering Armata (ARMP) growth (Underperforming) 2026-05-05Continuation Signals - newser.com
Study maps phage in Armata’s treatment candidate for lung infections - Stock Titan
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - marketscreener.com
ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92 - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Armata Pharmaceuticals : 2026 Annual Meeting Proxy - marketscreener.com
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
Armata Pharmaceuticals (NASDAQ: ARMP) 2026 proxy details pay, control and going concern risk - Stock Titan
Pfizer Inc. (PFE)Senior Commercial Leader Daniel B. Gilmer, Ph.D. Appointed to Armata Pharmaceuticals Board of DirectorsCertified Trade Ideas - newser.com
Armata Pharmaceuticals Appoints Pfizer Executive Daniel B. Gilmer, Ph.D. to Board to Advance Bacteriophage Therapeutics Commercialization 1 - Minichart
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Arm appoints Dr. Daniel Gilmer to Board effective April 24, 2026 - TradingView
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors – Company AnnouncementFT.com - Financial Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
ARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today.Geographic Trends - Xã Thanh Hà
ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors.Retail Trader Ideas - UBND thành phố Hải Phòng
12 Health Care Stocks Moving In Tuesday's Intraday SessionFirefly Neuroscience (NASDAQ:AIFF), AIxCrypt - Benzinga
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 6.4%Should You Sell? - MarketBeat
Buyback Watch: Is Armata Pharmaceuticals Inc a cyclical or defensive stock2026 Retail Activity & Daily Entry Point Trade Alerts - baoquankhu1.vn
Trend Report: Is Armata Pharmaceuticals Inc currently under institutional pressureWeekly Profit Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Earnings Beat: Is Armata Pharmaceuticals Inc currently under institutional pressure2026 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
ARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Armata (ARMP) Stock Ready to Rally | Price at $11.82, Up 16.16%Money Flow - Xã Vĩnh Công
Update Recap: What analysts say about Armata Pharmaceuticals Inc stockEarnings Risk Report & Long-Term Safe Investment Plans - baoquankhu1.vn
Finanzdaten der Armata Pharmaceuticals Inc-Aktie (ARMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):